Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Ligand Pharmaceuticals Incorporated < Previous 1 2 Next > Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio September 18, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) September 01, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Reports Second Quarter 2023 Financial Results August 08, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials July 27, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand To Report Second Quarter 2023 Financial Results On August 8 July 25, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Offers $15 Million to Acquire Assets of Novan, Inc. July 17, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) May 16, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Reports First Quarter 2023 Financial Results May 04, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand to Report First Quarter 2023 Financial Results on May 4, 2023 April 24, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Reports Fourth Quarter and Full Year 2022 Financial Results February 22, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy February 17, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND TVTX Ligand to Report Fourth Quarter Financial Results on February 22 February 06, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum January 06, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Pharmaceuticals Names Director Todd C. Davis as CEO December 05, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand to Hold Investor and Analyst Day on December 13 November 16, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Reports Third Quarter 2022 Financial Results November 07, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Announces Completion of OmniAb Spin-Off November 01, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Distribution of OmniAb Complete and Business Combination Closed November 01, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand to Report Third Quarter Financial Results on November 7 October 26, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma October 26, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND OmniAb Business Combination Approved by APAC Shareholders October 24, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers AHPA LGND Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) October 03, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off October 03, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma August 24, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers AHPA LGND Ligand Reports Second Quarter 2022 Financial Results August 08, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers AHPA LGND Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) August 01, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand to Report Second Quarter Financial Results on August 8 July 22, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors June 29, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Reports First Quarter 2022 Financial Results May 04, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers AHPA LGND Ligand to Report First Quarter Financial Results on May 4 April 19, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.